GV1001 clinical trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer's Disease

This study is testing a new medicine, GV1001, for people with mild to moderate Alzheimer's disease. We want to see if it's safe and if it can help improve memory and thinking over 52 weeks. Half the participants will receive the medicine, and half will receive a dummy injection.